TAS-115

CAS No. 1190836-34-0

TAS-115( H2OL3Q4XRD | 4-(2-Fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide | pamufetinib )

Catalog No. M23360 CAS No. 1190836-34-0

TAS-115 is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 162 In Stock
10MG 239 In Stock
25MG 406 In Stock
50MG 597 In Stock
100MG 851 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TAS-115
  • Note
    Research use only, not for human use.
  • Brief Description
    TAS-115 is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively).
  • Description
    TAS-115 is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively).
  • In Vitro
    Pamufetinib is ATP antagonism with inhibition constant (Ki) values against rVEGFR2 and rMET of 12 and 39 nM, respectively. Pamufetinib inhibits the kinase activity of both VEGFR2 and MET and their signal-dependent cell growth as strongly as other known VEGFR or MET inhibitors. Pamufetinib induces less damage in various normal cells than do other VEGFR inhibitors. Pamufetinib does not affect the growth of PC-9 or HCC827 cells at concentrations less than 10 μM; however, the combined use of Pamufetinib with erlotinib reverses HGF-induced resistance in the cell lines in a concentration-dependent manner. Pamufetinib inhibits VEGF production by cancer cells and endothelial proliferation.
  • In Vivo
    Pamufetinib (50 mg/kg/d) completely prevents tumor growth during the treatment period. Pamufetinib (200 mg/kg/d) induces a 48% regression from the initial tumor volume in MET-amplified human cancer transplanted models. The estimated 50% effective dose (ED50) of Pamufetinib in this model is 8 mg/kg/d. Pamufetinib significantly prolongs survival of these mice when administered at doses of 50 or 200 mg/kg/d. Pamufetinib inhibits angiogenesis in PC-9/HGF tumors in vivo. Moreover, the doublet erlotinib and Pamufetinib successfully inhibit PC-9/HGF tumor growth and delay tumor regrowth associated with sustained tumor vasculature inhibition even after cessation of the treatment.
  • Synonyms
    H2OL3Q4XRD | 4-(2-Fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide | pamufetinib
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR2|c-Met
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1190836-34-0
  • Formula Weight
    518.56
  • Molecular Formula
    C27H23FN4O4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CNC(c(cc1c(Oc(ccc(NC(NC(Cc2ccccc2)=O)=S)c2)c2F)ccnc1c1)c1OC)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Fujita H, et al. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile. Mol Cancer Ther. 2013 Dec;12(12):2685-96.
molnova catalog
related products
  • AG-13958

    AG-13958 (AG-013958) a potent VEGFR tyrosine kinase inhibitor ?for the treatment of age-related macular degeneration.

  • Tivozanib

    A highly potent inhibitor of pan-VEGFR with IC50s of 60/6.5/15 nM for VEGFR1/2/3.

  • Regorafenib

    A potent multikinase inhibitor that potently inhibits these endothelial cell kinases in biochemical and cellular kinase phosphorylation assays with nanomolar range (IC50=3-200 nM).